RecruitingPhase 2NCT07162480
Phase II Trial of Puxitatug Samrotecan (AZD8205) in Advanced, Recurrent or Metastatic (R/M) Aggressive Adenoid Cystic Carcinoma Subtype I (ACC-I)
Sponsor
M.D. Anderson Cancer Center
Enrollment
28 participants
Start Date
Apr 29, 2026
Study Type
INTERVENTIONAL
Conditions
Summary
Phase II open label study designed to evaluate the efficacy and safety of P-Sam in patients with aggressive, solid, NOTCH mutant or p63 low (B7-H4 high) R/M ACC-I patients.
Eligibility
Min Age: 18 Years
Plain Language Summary
Simplified for easier understanding
This clinical trial is studying a drug called P-Sam for people with adenoid cystic carcinoma. The study is currently recruiting participants at 1 location. People eligible for this study include aged 18 Years and older.
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
DRUGP-Sam
Given by IV
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07162480
Related Trials
Clinical Trial of HG146 Administered to Participants With Adenoid Cystic Carcinoma
NCT067815671 location
CB-103 With Either Lenvatinib or Abemaciclib in Patients With NOTCH ACC
NCT057748991 location
A Study of Enfortumab Vedotin in People With Adenoid Cystic Carcinoma
NCT068915607 locations
A Study of Becotatug Vedotin (MRG003) Combined With Epirubicin as Neoadjuvant Therapy for EGFR-Positive, Unresectable Recurrent Sinonasal Adenoid Cystic Carcinoma
NCT075228791 location
A Study of Emiltatug Ledadotin (Emi-Le) in Participants With Solid Tumors
NCT0537799626 locations